EDAP TMS (FOCL) Aktienübersicht
EDAP TMS S.A., das unter dem Namen FocalTherics firmiert, ist ein Medizintechnikunternehmen, das nicht-invasive therapeutische Ultraschall- und energiebasierte Medizinprodukte in Asien, Frankreich, den Vereinigten Staaten und international entwickelt, herstellt, vermarktet und verkauft. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
FOCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
EDAP TMS S.A. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$4.15 |
| 52-Wochen-Hoch | US$6.40 |
| 52-Wochen-Tief | US$1.75 |
| Beta | -0.070 |
| 1 Monat Veränderung | 0.48% |
| 3 Monate Veränderung | -15.31% |
| 1 Jahr Veränderung | 66.00% |
| 3 Jahre Veränderung | -36.06% |
| 5 Jahre Veränderung | -33.39% |
| Veränderung seit IPO | -51.18% |
Aktuelle Nachrichten und Updates
Recent updates
Narrative-Update • Aug 01
FOCL: Rising Ultrasound Adoption And New Indications Will Support Future Re Rating
Analysts raised their fair value estimate for EDAP TMS from $10.00 to $15.00, citing Street research that notes growing interest in high intensity focused ultrasound for prostate cancer, along with additional optionality in benign prostatic hyperplasia and endometriosis indications. Analyst Commentary Bullish analysts see EDAP TMS as a focused play on high intensity focused ultrasound for prostate cancer, with added potential in benign prostatic hyperplasia and endometriosis.
Narrative-Update • Jul 17
FOCL: Prostate Cancer Ultrasound Adoption Will Drive Longer Term Upside
The updated analyst price target for EDAP TMS increases from approximately $6.83 to $8.50. Analysts cite growing interest in high-intensity focused ultrasound for prostate cancer, along with potential upside from benign prostatic hyperplasia and endometriosis applications, as key supports for this revision.
Narrative-Update • Jun 23
FOCL: Execution And Margin Risks Will Limit Upside Versus Current Pricing
EDAP TMS’s analyst fair value estimate has been reset from $2.50 to $3.00 as analysts factor in updated assumptions on growth, margins and valuation following recent sector research, including coverage of peers in high intensity focused ultrasound technology for prostate cancer treatment. Analyst Commentary Recent Street research on EDAP TMS highlights a mix of optimism around the company’s high intensity focused ultrasound platform and caution around how that potential is reflected in the valuation.Narrative-Update • Jun 04
FOCL: Reaffirmed Outlook And Fair Value Will Support Future Re Rating
Analysts have reduced their price target on EDAP TMS by $4 to reflect updated assumptions on the discount rate, revenue growth, profit margins and future P/E, while maintaining a $10.00 fair value estimate. What's in the News EDAP TMS plans to change its Nasdaq Global Market ticker symbol from EDAP to FOCL, effective June 1, 2026.Narrative-Update • May 21
EDAP: Reaffirmed 2026 Outlook Will Support Discount Rate Recalibration
Analysts have lowered their price target on EDAP TMS by $4, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Bullish analysts highlight that the revised price target, while reduced by US$4, still reflects confidence in EDAP TMS's ability to execute on its business plan and support a valuation that they view as attractive relative to updated assumptions.Narrative-Update • Apr 27
EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis
Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.Narrative-Update • Apr 12
EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution
Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.Narrative-Update • Mar 29
EDAP: Longer Term Revenue Outlook Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to $6.83. The change reflects updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are now more closely aligned with their current modeling for the business.Narrative-Update • Mar 14
EDAP: 2026 Segment Guidance Will Limit Upside Versus Current Pricing
Analysts have adjusted their price target on EDAP TMS to reflect updated assumptions for revenue growth, profit margins, discount rate and future P/E. This has led to a revised valuation framework that investors should watch closely against the current share price in dollar terms.Narrative-Update • Feb 28
EDAP: 2026 Segment Guidance Will Constrain Future Share Price Upside
Analysts have lifted their EDAP TMS price target to reflect updated assumptions for a $2.50 fair value, a slightly higher discount rate, a shift from a 1.0% revenue decline to 20.8% growth expectations, a modestly stronger 13.40% profit margin outlook, and a lower forward P/E of about 11.6x. What's in the News EDAP TMS issued revenue guidance for 2026 for its HIFU business, with a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million.Narrative-Update • Feb 14
EDAP: Flat Revenue Outlook And Higher P/E Assumptions Will Limit Upside
Analysts have raised their $ fair value estimate for EDAP TMS from $1.50 to $2.50, citing updated assumptions that include a lower discount rate, a revenue growth outlook that is closer to flat, slightly higher profit margins, and a higher future P/E multiple. What's in the News Issued 2026 revenue guidance for the HIFU business in a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million (company guidance).Analyseartikel • Feb 03
EDAP TMS S.A. (NASDAQ:EDAP) Shares Fly 32% But Investors Aren't Buying For Growth
EDAP TMS S.A. ( NASDAQ:EDAP ) shares have continued their recent momentum with a 32% gain in the last month alone...Narrative-Update • Jan 31
EDAP: HIFU Guidance And FDA Clearance Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to US$25.18 from US$26.39, citing updated assumptions for the discount rate, profit margin and future P/E, which leave their fair value view broadly unchanged. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million, also provided in euro terms as €43.0 million to €46.0 million and €19.0 million to €22.0 million respectively (company guidance).Narrative-Update • Jan 17
EDAP: Future Guidance And FDA Clearance Will Support Bullish Upside
Analysts now see higher upside for EDAP TMS, lifting their fair value estimate from about US$5.77 to roughly US$6.83 as they factor in slightly different assumptions around discount rate, revenue growth, profit margins and future P/E levels. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million (Key Developments).Analyseartikel • Dec 20
EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Right But Growth Is Lacking After Shares Rocket 32%
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders would be excited to see that the share price has had a great month, posting...Analyseartikel • Dec 13
EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative-Update • Aug 29
CE Mark And Global Expansion Will Elevate HIFU Adoption
Despite a modest decline in consensus revenue growth forecasts, EDAP TMS’s sharply higher projected P/E multiple suggests increased investor optimism regarding future earnings quality or profitability, driving the analyst price target up from $5.75 to $14.00. What's in the News EDAP TMS raised its 2025 core HIFU business revenue growth guidance to 26%-34% year over year, up from the previous 16%-25% range.Analyseartikel • Aug 19
There Is A Reason EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Undemanding
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a strong buy right now...Analyseartikel • Jul 03
Is EDAP TMS (NASDAQ:EDAP) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • May 18
Improved Revenues Required Before EDAP TMS S.A. (NASDAQ:EDAP) Stock's 28% Jump Looks Justified
Those holding EDAP TMS S.A. ( NASDAQ:EDAP ) shares would be relieved that the share price has rebounded 28% in the last...
Neues Narrative • Apr 08
CE Mark And Global Expansion Will Elevate HIFU Adoption
New approvals and strategic collaborations enhance EDAP TMS's market opportunities, potentially driving future revenue growth and improving margins.Analyseartikel • Apr 03
EDAP TMS S.A. (NASDAQ:EDAP) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Analyseartikel • Mar 15
Is EDAP TMS (NASDAQ:EDAP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Dec 25
Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk
With a price-to-sales (or "P/S") ratio of 1.2x EDAP TMS S.A. ( NASDAQ:EDAP ) may be sending very bullish signals at the...Analyseartikel • Oct 24
Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Sep 07
Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 35...Analyseartikel • Jul 24
Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right now...Analyseartikel • Mar 22
There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump
Despite an already strong run, EDAP TMS S.A. ( NASDAQ:EDAP ) shares have been powering on, with a gain of 28% in the...Analyseartikel • Mar 03
Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jan 19
It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...Analyseartikel • Aug 11
Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a sell right now...Aktionärsrenditen
| FOCL | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 1.2% | 1.6% | -0.2% |
| 1Y | 66.0% | -16.2% | 12.1% |
Rendite im Vergleich zur Industrie: FOCL übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -16.2 erzielte.
Rendite vs. Markt: FOCL übertraf den Markt US, der im vergangenen Jahr eine Rendite von 12.1 erzielte.
Preisvolatilität
| FOCL volatility | |
|---|---|
| FOCL Average Weekly Movement | 7.9% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: FOCL hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: FOCLDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1979 | 289 | Ryan Rhodes | investor.focalone.com |
EDAP TMS S.A., handelnd unter dem Namen FocalTherics, ist ein Medizintechnikunternehmen, das nicht-invasive therapeutische Ultraschall- und energiebasierte medizinische Geräte in Asien, Frankreich, den Vereinigten Staaten und international entwickelt, herstellt, vermarktet und vertreibt. Das Unternehmen entwickelt, fertigt, vermarktet und vertreibt nicht-invasive robotergestützte HIFU-Systeme für urologische und andere Indikationen. Es bietet auch Focal One, ein robotergestütztes HIFU-System zur Behandlung von Patienten mit Prostatakrebs, sowie Einwegartikel, Leasing und behandlungsbezogene Dienstleistungen und Wartungsdienste an.
EDAP TMS S.A.'s Grundlagenzusammenfassung
| FOCL grundlegende Statistiken | |
|---|---|
| Marktanteil | US$190.70m |
| Gewinn(TTM) | -US$39.12m |
| Umsatz(TTM) | US$79.31m |
2.4x
Kurs-Umsatz-Verhältnis-4.9x
Kurs-Gewinn-Verhältnis Ist FOCL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| FOCL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$79.31m |
| Kosten der Einnahmen | US$44.03m |
| Bruttogewinn | US$35.28m |
| Sonstige Ausgaben | US$74.40m |
| Gewinn | -US$39.12m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.85 |
| Bruttomarge | 44.49% |
| Nettogewinnspanne | -49.32% |
| Schulden/Eigenkapital-Verhältnis | -1,237.4% |
Wie hat sich FOCL auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/20 10:45 |
| Aktienkurs zum Tagesende | 2026/09/18 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
EDAP TMS S.A. wird von 9 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| null null | CG Capital |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |